LH Stock Bolstered by FDA's COVID-19 Test Kit Approval

The tests will be prioritized for healthcare workers

Deputy Editor
Apr 21, 2020 at 10:44 AM
facebook twitter linkedin


Laboratory Corp. of America Holdings (NYSE:LH) is higher this morning after the Food and Drug Administration (FDA) granted emergency use authorization to its COVID-19 at-home test kit. Healthcare workers are taking priority, while the company intends on making the kits available to the greater public in "coming weeks." In response, LH is up 2.7% to trade at $149.57.

The pop puts LH back north of its 40-day moving average -- a trendline the equity has only closed atop one other time since March 5, though pressure at the 50-day moving average now looms overhead. The $150 level, which coincides with the stock's post-bear gap highs, is also acting as a ceiling. 

The majority of analysts covering LH are optimistic, with nine out of 12 rating it a “buy” or better. Plus, the consensus 12-month price target of $177.07 sits at a 21.6% premium to current levels.

On the other hand, the equity's Schaeffer's put/call open interest ratio (SOIR) of 0.70, sits higher than 98% of all other readings from the past year, suggesting short-term option players have rarely been more put-biased in the past 12 months.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners